Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

  • Technology appraisal guidance
  • TA284
  • Published: 
Download guidance (PDF)

5 Implementation

5.1 NICE has developed tools to help organisations put this guidance into practice (listed below).

  • A costing statement explaining the resource impact of this guidance.